SecBot SecBot
SECBOTREPLAY Home › Report › URGN

URGN · ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined to…

UroGen Pharma Ltd. · PRESS-RELEASE filed Nov 4, 2026 at 08:00 ET

At the news

BEARISHIMPACT 6/10

PRESS-RELEASE filed Nov 4, 2026 at 08:00 ET

ZUSDURI revenue grew 35% QoQ to $68.0M, but JELMYTO revenue declined to $21.0M and full-year JELMYTO guidance was lowered to ~$90M from $97-101M. The FDA accepted the UGN-103 NDA with a PDUFA date of June 14, 2027.

  • Total revenue $89.0M vs. $89.9M consensus (slight miss)
  • ZUSDURI net product revenue $68.0M, up 35% QoQ
  • JELMYTO net product revenue $21.0M, down from $25.7M YoY
  • Full-year 2026 JELMYTO revenue guidance lowered to ~$90M from $97-101M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access